Vitamin A Replacement in Patients Undergoing HSCT and Its Role on MBI-LCBI Rates

Completed · Not applicable

Conditions studied: Hematopoietic Stem Cell Transplant

In brief

The primary objective of this study is to establish that single dose vitamin A supplementation is feasible and safe in pediatric and young adult bone marrow transplant recipients until day +30 (± 7 days) after hematopoietic stem cell transplantation.

Key facts

Study ID

NCT03039257

Run by

Children's Hospital Medical Center, Cincinnati

People needed

12

Starts

2017-02-02

Expected to finish

2018-03-28

Last updated by the study team

2018-05-30

Who can join

Age: 1 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Any patient undergoing HSCT.

You may not qualify if…

• Vitamin A hypersensitivity or allergy.
• Age less than 1 year at time of transplant.
• Baseline pre-HSCT vitamin A levels higher than the upper quartile of normal range for age.
• Enteral feeding or medication intolerance.
• Pregnancy.

Where it is running

• Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.